Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Key Inclusion Criteria: * Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, histologically diagnosed high-grade serous * Platinum-resistant disease (relapsing within 3-6 months after completion of initial platinum-based treatment). Patients progressing at any time on or after ≥ 2nd platinum-based therapy are eligible. * Received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy * Evidence of progressive disease * Measurable disease (RECIST v1.1) with at least one non-target lesion accessible by image-guided biopsy. No single lesion may be larger than 4 cm in diameter. * Completed pre-treatment tumor biopsy and willing to undergo on-treatment tumor biopsy * ECOG 0-1 * Live expectancy ≥ 6 months * Meet protocol-specified laboratory requirements Key Exclusion Criteria: * Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy * Prior receipt of survivin-based vaccines/therapy, immune checkpoint inhibitors, IDO inhibitor, or cell-based therapy * Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum * Clinical ascites * Concurrent second malignancy other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission * GI condition that might limit absorption of oral agents * Recent history of thyroiditis * History of autoimmune disease requiring treatment within the last two ye…